BVF INC/IL
CIK
1056807
Location
San Francisco, CA
Portfolio Value
Mid
$3,588,099,763
Diversification
Diversified
Reports for
BVF PARTNERS L P/IL
Filing Date
Global Rank
#936
/ 8,700
▲ 177
Top Industry
Biotechnology
95.9%
Period ended 2 months ago
Filed Aug 14, 2026 · 30d
26 quarters · since Mar 2020
Clone Performance
Sep 2026–Sep 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
-1.6%
SPY
+0.9%
Annualised alpha
—
Max drawdown
−1.6%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Returns are unavailable when a held security or benchmark crosses a captured split without a certified price basis; the requested window is not shortened to hide it. It tracks 100% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
44 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
15.5%
+0.5 pts
Top 5
48.1%
+2.7 pts
Top 10
65.5%
+1.6 pts
HHI
659
Diversified+50
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.9% | $3,582,749,763 |
| Financial Services | 0.1% | $5,350,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IVVD | Invivyd, Inc. | +8,640,000 | 28,165,000 | $24,559,880 | |
| — | +5,003,000 | 7,593,303 | $0 | ||
| OKUR | OnKure Therapeutics, Inc. | +1,256,806 | 3,235,778 | $14,755,147 | |
| AVTX | Avalo Therapeutics, Inc. | +442,700 | 2,075,545 | $38,356,071 | |
| ALKS | Alkermes plc. | +154,704 | 2,154,704 | $112,906,489 | |
| RVMD | Revolution Medicines, Inc. | +108,378 | 2,965,160 | $555,315,164 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
9 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IMUX | Immunic, Inc. | −6,887,677 | 765,295 | $11,762,584 | |
| KYMR | Kymera Therapeutics, Inc. | −1,630,658 | 3,872,052 | $444,008,202 | |
| MIRM | Mirum Pharmaceuticals, Inc. | −528,700 | 1,056,027 | $123,629,080 | |
| TYRA | Tyra Biosciences, Inc. | −500,000 | 1,476,196 | $47,149,700 | |
| PVLA | Palvella Therapeutics, Inc. | −288,200 | 672,789 | $102,815,614 | |
| NKTR | Nektar Therapeutics | −168,520 | 2,391,075 | $166,920,945 | |
| IRON | Disc Medicine, Inc. | −118,700 | 1,153,612 | $84,375,181 | |
| GPCR | Structure Therapeutics Inc. | −92,535 | 3,366,823 | $180,697,390 | |
| ZYME | Zymeworks Inc. | −85,000 | 3,649,142 | $95,388,571 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
6 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | 2,350,000 | $29,939,000 | |
| ABSI | Absci Corp | 2,361,674 | $27,371,801 | |
| SGMT | Sagimet Biosciences Inc. | 2,500,000 | $19,325,000 | |
| RACC | Research Alliance Corp III | 500,000 | $5,350,000 | |
| ENTX | Entera Bio Ltd. | 2,425,000 | $4,292,250 | |
| ENGN | enGene Therapeutics Inc. | 945,402 | $0 | |
| No positions match the current search. | ||||
44 tracked positions ·
$3,588,099,763 total
· filing declares
44 positions · $3,910,995,502
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 2,965,160 | $555,315,164 | 15.48% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 3,872,052 | $444,008,202 | 12.37% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
Held | 16,001,284 | $311,544,999 | 8.68% | |
| GHRS |
GH Research PLC
Healthcare
|
Held | 8,650,158 | $232,516,247 | 6.48% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Reduced | 3,366,823 | $180,697,390 | 5.04% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
Reduced | 2,391,075 | $166,920,945 | 4.65% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Reduced | 1,056,027 | $123,629,080 | 3.45% | |
| XNCR |
Xencor Inc
Healthcare
|
Held | 7,133,720 | $114,852,892 | 3.20% | |
| ALKS |
Alkermes plc.
Healthcare
|
Added | 2,154,704 | $112,906,489 | 3.15% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Held | 4,460,886 | $107,953,441 | 3.01% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Held | 5,750,683 | $104,719,937 | 2.92% | |
| PVLA |
Palvella Therapeutics, Inc.
Healthcare
|
Reduced | 672,789 | $102,815,614 | 2.87% | |
| ZYME |
Zymeworks Inc.
Healthcare
|
Reduced | 3,649,142 | $95,388,571 | 2.66% | |
| KURA |
Kura Oncology, Inc.
Healthcare
|
Held | 8,445,769 | $92,650,085 | 2.58% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Reduced | 1,153,612 | $84,375,181 | 2.35% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Held | 2,547,557 | $83,356,065 | 2.32% | |
| OLMA |
Olema Pharmaceuticals, Inc.
Healthcare
|
Held | 5,295,893 | $66,251,621 | 1.85% | |
| ANNX |
Annexon, Inc.
Healthcare
|
Held | 8,698,173 | $49,666,567 | 1.38% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,748,763 | $49,477,734 | 1.38% | |
| ACIU |
AC Immune SA
Healthcare
|
Held | 19,822,436 | $47,177,397 | 1.31% | |
| TYRA |
Tyra Biosciences, Inc.
Healthcare
|
Reduced | 1,476,196 | $47,149,700 | 1.31% | |
| STRO |
Sutro Biopharma, Inc.
Healthcare
|
Held | 1,251,788 | $41,559,361 | 1.16% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Held | 1,294,463 | $41,099,200 | 1.15% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Added | 2,075,545 | $38,356,071 | 1.07% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
Held | 2,879,289 | $38,294,543 | 1.07% | |
| QTTB |
Q32 Bio Inc.
Healthcare
|
NEW | 2,350,000 | $29,939,000 | 0.83% | |
| AVR |
Anteris Technologies Global Corp.
Healthcare
|
Held | 3,000,000 | $29,550,000 | 0.82% | |
| FHTX |
Foghorn Therapeutics Inc.
Healthcare
|
Held | 5,842,000 | $28,508,960 | 0.79% | |
| ABSI |
Absci Corp
Healthcare
|
NEW | 2,361,674 | $27,371,801 | 0.76% | |
| ELDN |
Eledon Pharmaceuticals, Inc.
Healthcare
|
Held | 6,293,282 | $24,795,531 | 0.69% | |
| IVVD |
Invivyd, Inc.
Healthcare
|
Added | 28,165,000 | $24,559,880 | 0.68% | |
| SGMT |
Sagimet Biosciences Inc.
Healthcare
|
NEW | 2,500,000 | $19,325,000 | 0.54% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
Added | 3,235,778 | $14,755,147 | 0.41% | |
| IMUX |
Immunic, Inc.
Healthcare
|
Reduced | 765,295 | $11,762,584 | 0.33% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Held | 2,233,742 | $10,431,575 | 0.29% | |
| IMA |
ImageneBio, Inc.
Healthcare
|
Held | 1,110,002 | $6,549,011 | 0.18% | |
| TCRX |
TScan Therapeutics, Inc.
Healthcare
|
Held | 5,564,290 | $5,453,004 | 0.15% | |
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 500,000 | $5,350,000 | 0.15% | |
| MOLN |
Molecular Partners AG
Healthcare
|
Held | 1,353,968 | $5,239,856 | 0.15% | |
| TENX |
Tenax Therapeutics, Inc.
Healthcare
|
Held | 339,549 | $4,940,437 | 0.14% | |
| ENTX |
Entera Bio Ltd.
Healthcare
|
NEW | 2,425,000 | $4,292,250 | 0.12% | |
| IVA |
Inventiva S.A.
Healthcare
|
Held | 686,040 | $2,593,231 | 0.07% | |
|
|
Added | 7,593,303 | $0 | 0.00% | ||
| ENGN |
enGene Therapeutics Inc.
Healthcare
|
NEW | 945,402 | $0 | 0.00% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.